Answers are grounded in this paper and cite their sources.
Gaucher disease (GD) is a rare autosomal recessive lysosomal storage disorder caused by pathogenic variants in the GBA1 gene, resulting in deficient glucocerebrosidase activity and accumulation of glucosylceramide within macrophages. Three main clinical forms are distinguished according to the presence and extent of central nervous system involvement: non-neuronopathic type 1 (GD1), acute neuronopathic type 2, and chronic neuronopathic type 3. The disease presents with a broad spectrum of manifestations, including hepatosplenomegaly, thrombocytopenia, skeletal complications, pulmonary involvement, and neurological symptoms in neuronopathic forms. This position statement of the Polish Society for Inborn Errors of Metabolism summarizes current recommendations for the diagnosis, treatment, and monitoring of patients with GD. The document discusses the molecular background, epidemiology, clinical presentation, diagnostic algorithms, biomarkers, imaging modalities, and severity assessment tools. Particular attention is given to enzyme replacement therapy, which remains the standard of care for GD1 and type 3 GD, and to substrate reduction therapy with eliglustat in selected adults with GD1. The role of supportive treatment, management during pregnancy, monitoring of therapeutic efficacy, multidisciplinary care, and transition from pediatric to adult services is also addressed. Emerging therapeutic approaches, including pharmacological chaperones and gene therapy, are reviewed. The recommendations emphasize early diagnosis, individualized treatment, and long-term follow-up in specialized reference centers.
No takes yet. Share an insight, caveat, or question.
Kieć‐Wilk et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: